Stock KERYX BIOPHARMACEUTICALS
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Keryx Biopharmaceuticals

Equities

US4925151015

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Keryx Biopharmaceuticals Stockholders Approve Merger with Akebia Therapeutics
GL
Keryx Biopharmaceuticals : ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
PU
ISS Recommends that Keryx Biopharmaceuticals Stockholders Vote “FOR” the Proposed Merger with Akebia Therapeutics
GL
Keryx Biopharmaceuticals : Akebia Therapeutics and Keryx Biopharmaceuticals Announce Chairperson for Combined Company
BU
Keryx Biopharmaceuticals Announces Third Quarter 2018 Financial Results
GL
Keryx Biopharmaceuticals to Release Third Quarter 2018 Financial Results on Thursday, November 8, 2018
GL
Keryx Biopharmaceuticals Announces Participation in an Upcoming Investor Conference
GL
Keryx Biopharmaceuticals : Announces Second Quarter 2018 Financial Results
PU
Keryx Biopharmaceuticals Announces Second Quarter 2018 Financial Results   
GL
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2018 Financial Results on Wednesday, August 8, 2018
GL
Keryx Biopharmaceuticals : Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
BU
Keryx Biopharmaceuticals Announces Participation in a Renal Disease Panel at the JMP Securities Life Sciences Conference on Thursday, June 21st
GL
Keryx Pharmaceuticals Announces Upcoming Investor Presentations
GL
Keryx Biopharmaceuticals Announces Data from an Investigator Sponsored Trial of Ferric Citrate in Patients with Advanced Chronic Kidney Disease in a Late-Breaking Presentation at the 55th Annual ERA/EDTA Today in Copenhagen
GL
Keryx Biopharmaceuticals Announces First Quarter 2018 Financial Results
GL
Keryx Biopharmaceuticals Announces Changes to Management and Preliminary First Quarter 2018 Revenue
GL
Keryx Biopharmaceuticals Announces Late-breaking Ferric Citrate Abstract Accepted for Presentation at the 55th ERA-EDTA Congress
GL
Keryx Biopharmaceuticals Receives 2018 Corporate Innovator Award from the National Kidney Foundation
GL
Keryx Biopharmaceuticals Announces Publication of Data from the Phase 3 Trial of Auryxia® (ferric citrate) for Iron Deficiency Anemia in Patients with Chronic Kidney Disease, Not on Dialysis, in the American Journal of Hematology
GL
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Keryx Biopharmaceuticals
  5. Press Releases